Covid drug: Natco eyes patent waiver

Making its case, Natco’s application said Olumiant is not manufactured in India — less than 9,000 tablets were imported in 2019 and 2020, at an average cost of Rs 3,230 per tablet. Citing the pricing as a significant barrier, it said a 14-day regimen (one tablet a day) works out to approximately Rs 45,220 per patient, which most Indians can ill-afford.

from Markets-Economic Times https://ift.tt/3b8d95E
via IFTTT https://ift.tt/3unrq65